000650 Renhe Pharmacy
- 6.55
- -0.24-3.53%
Renhe Pharmacy News
Renhe Pharmacy Gets 58 Million Yuan in Government Grants
Renhe Pharmacy (SHE:000650) received 58.4 million yuan in income-related enterprise support funds from the municipality of China's Zhangshu City, according to the company's filing on the Shenzhen Stoc
Express News | Renhe Pharmaceutical: Received a government subsidy of 584.354 million yuan
Renhe Pharmaceutical (000650.SZ): The repurchase has completed a cumulative total of 1.107% shares have been repurchased
Gelonghui, April 1, 丨 Renhe Pharmaceutical (000650.SZ) announced that the time period for the company's actual share repurchase was from December 8, 2023 to March 29, 2024. The cumulative number of shares repurchased through centralized bidding transactions through the repurchase special securities account was 15,500,000 shares, accounting for 1.1072% of the company's total share capital. The maximum transaction price of the repurchase was 6.78 yuan/share, and the minimum transaction price was 5.18 yuan/share, and the total transaction amount was about RMB 100 million (excluding transaction fees).
Express News | March 4 noon announcement: Inteltech plans to build a new complete equipment project with an annual output of 1,000 sets of evaporative condensers
Renhe Pharmaceutical (000650.SZ) subsidiary obtained the drug registration certificate for sodium hyaluronate eye drops
Renhe Pharmaceutical (000650.SZ) issued an announcement. The company's subsidiary Jiangxi Shanliang Pharmaceutical Co., Ltd. recently received the national...
Renhe Pharmaceutical (000650.SZ): 1.00% of shares have been cumulatively repurchased
Gelonghui on March 1, 丨 Renhe Pharmaceutical (000650.SZ) announced that as of February 29, 2024, the company had repurchased 14,000,000 shares of the company's shares through a dedicated securities account, accounting for 1.00% of the company's current total share capital (1,399,938,234 shares). The highest transaction price of the repurchase was 6.78 yuan/share, and the minimum transaction price was RMB 5.18 yuan/share, and the total transaction amount was RMB 90,3236 million (excluding transaction fees).
Renhe Pharmaceutical (000650.SZ): A total cost of 806.18,400 yuan to buy back 12.3 million shares
Gelonghui, February 1, 丨 Renhe Pharmaceutical (000650.SZ) announced that as of January 31, 2024, the company had repurchased a total of 12.3 million shares of the company's shares through a special stock repurchase account, accounting for 0.8786% of the company's current total share capital. The highest transaction price for the repurchase was 6.78 yuan/share, the minimum transaction price was 5.76 yuan/share, and the total amount paid was 806.184,000 yuan (excluding transaction fees).
Renhe Pharmaceutical (000650.SZ): A total cost of 6.0723 million yuan to buy back 9 million shares
Gelonghui, January 2, 丨 Renhe Pharmaceutical (000650.SZ) announced that as of December 31, 2023, the company had repurchased 9 million shares of the company's shares through a special stock repurchase securities account, accounting for 0.6429% of the company's current total share capital. The highest transaction price for the repurchase was 6.78 yuan/share, the minimum transaction price was 6.40 yuan/share, and the total amount paid was 6.723 million yuan (excluding transaction fees).
Renhe Pharmaceutical (000650.SZ): The company's cold medicine sales are normal
Gelonghui December 18丨Renhe Pharmaceutical (000650.SZ) said on the investor interactive platform that the company's cold medicine sales are normal. Judging from Ren Colic's data for the first three quarters of 2023, revenue increased 97% year on year.
Renhe Pharmaceutical (000650.SZ): Production or sale of children's drugs with a wide range of product regulations
Glonghui December 15: Some investors asked Renhe Pharmaceutical (000650.SZ) on the investor interactive platform, “Has your company expanded the R&D and production volume of children's medicines?” The company replied that the company produces or sells many categories of children's drugs, and that products under development include oseltamivir phosphate dry suspensions, etc.
Renhe Pharmaceutical (000650.SZ): The initial repurchase of 570,000 shares involved 38625 million yuan
Gelonghui, December 8, Renhe Pharmaceutical (000650.SZ) announced that on December 8, 2023, for the first time, the company repurchased 570,000 shares of the company through centralized bidding through a special stock repurchase account, accounting for 0.04% of the company's current total share capital, with a maximum transaction price of 6.78 yuan/share and a minimum transaction price of 6.77 yuan/share, with a total transaction amount of 3.8625 million yuan (excluding transaction fees).
Renhe Pharmaceutical (000650.SZ): Plans to spend 80 million yuan to 150 million yuan to buy back the company's shares
On December 7, Gelonghui丨Renhe Pharmaceutical (000650.SZ) announced that the company plans to use its own capital to repurchase the company's shares through centralized bidding transactions. The total capital of this repurchase is not less than RMB 8000 million (inclusive) and no more than RMB 150.00 million (inclusive). The price of the repurchased shares does not exceed RMB 8.00 per share (inclusive), and the upper price limit of the repurchased shares does not exceed 150% of the average closing price of the company's shares for the 30 trading days prior to the board's decision. According to the estimate of the lower repurchase amount and the upper repurchase price limit, the number of shares that can be repurchased this time is estimated to be about 1000.0
Renhe Pharmaceutical (000650.SZ): Chairman Yang Xiao completed a 1.04% increase in shares
Gelonghui announced on November 1: Renhe Pharmaceutical (000650.SZ). As of the disclosure date of the announcement, the plan to increase holdings has been implemented. Mr. Yang Xiao, the chairman of the company, increased his holdings of the company's shares by a total of 14.5775 million shares through centralized bidding transactions, accounting for 1.0413% of the company's total share capital. The total increase in holdings was about 101 million yuan (excluding transaction expenses, etc.).
Yang Xiao, Chairman of Renhe Pharmaceutical (000650.SZ), increased his holdings by a total of 1,4017,500 shares
Renhe Pharmaceutical (000650.SZ) announced that Yang Xiao, chairman of the company, will focus until October 31, 2023...
Renhe Pharmaceutical (000650.SZ): Chairman Yang Xiao has increased his shares by a total of 1.0013%
On October 31, Gelonghui, Renhe Pharmaceutical (000650.SZ), announced that as of October 31, 2023, Mr. Yang Xiao, the chairman of the company, used his own funds to increase his holdings of the company's shares by a total of 14,017,500 shares through centralized bidding through the Shenzhen Stock Exchange trading system. The total transaction amount was 97.0566.62 million yuan (excluding transaction and other expenses), accounting for 1.0013% of the company's total share capital, and the increase ratio has reached 1%.
Renhe Pharmaceutical (000650.SZ): Pediatric aminophenolamine granules produced and sold can also be used to prevent and treat influenza in children
Glonghui, Oct. 16 | Renhe Pharmaceutical (000650.SZ) said on the investor interactive platform that Mycoplasma pneumoniae is a microorganism between bacteria and viruses that is easily spread through droplets or direct contact in crowded and poorly ventilated environments. The pediatric aminophenolamide granules (yucadan) produced and sold by the company are suitable for relieving symptoms such as fever, headache, limb pain, sneezing, runny nose, nasal congestion, and sore throat caused by the common cold and influenza in children. They can also be used to prevent and treat influenza in children.
Yang Xiao, Chairman of Renhe Pharmaceutical (000650.SZ), has increased his holdings by 8.29 million shares
Renhe Pharmaceutical (000650.SZ) issued an announcement. As of October 8, 2023, Yang Xiaoxian, chairman of the company...
Renhe Pharmaceutical (000650.SZ): The first phase of the employee stock ownership plan has all been sold through centralized bidding
Gelonghui, September 28, 丨 Renhe Pharmaceutical (000650.SZ) announced that as of September 28, 2023, all of the company's first-phase employee shareholding plan shares had been sold through second-level centralized bidding. The number of shares was 10,190,000 shares, accounting for 0.7279% of the company's total share capital of 1,399,938,234 shares.
Renhe Pharmaceutical (000650.SZ) subsidiary obtained the drug registration certificate for atorvastatin calcium tablets
Renhe Pharmaceutical (000650.SZ) issued an announcement. Jiangxi Pharmaceutical Co., Ltd., a subsidiary of the company, recently received the State...
The Chinese medicine sector fluctuated higher, and Taiji Group rose nearly 7%
Gelonghui September 11 | Taiji Group rose nearly 7%, while Renhe Pharmaceutical, Lingrui Pharmaceutical, Longjin Pharmaceutical, and Kangyuan Pharmaceutical rose more than 4%.
Analysis
Price Target
No Data
